TrialThe oncologist2026

Clinical management of adverse events in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with tucatinib, trastuzumab, and capecitabine.

Alicia F C Okines et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.